Live Breaking News & Updates on Fruquintinib|Page 3

Stay updated with breaking news from Fruquintinib. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

FRESCO-2: A Global Phase 3 Multiregional Clinical Trial Evaluating the Efficacy and Safety of Fruquintinib in Patients With Refractory Metastatic Colorectal Cancer

Arvind Dasari, MD, MS, presents data from the FRESCO-2 clinical trial evaluating fruquintinib in patients with refractory metastatic colorectal cancer, and provides insights on the clinical implications of the results. ....

Arvind Dasari , Global Phase , Clinical Trial Evaluating , Patients With Refractory Metastatic Colorectal , Partnership With , Colorectal Cancer , Refractory Metastatic Colorectal Cancer , Metastatic Colorectal Cancer , Fresco 2 , Fresco 2 Trial , Fresco 2 Study , Clinical Trial , Overall Survival ,

Hutchmed's sovleplenib meets primary, secondary endpoints in China phase III ITP trial

Hutchmed (China) Ltd.’s sovleplenib (HMPL-523) met the primary endpoint of durable response rate and all secondary endpoints in the pivotal phase III trial in adults with primary immune thrombocytopenia (ITP) in China. ....

Hutchmed China Ltd , Hutchmed China Ltd , Hmpl 523 , Primary Immune Thrombocytopenia , Warm Antibody Autoimmune Hemolytic Anemia , Indolent Non Hodgkin Lymphoma ,

Fruquintinib significantly improves survival in patients with refractory metastatic colorectal cancer

1. Overall survival was significantly greater in the fruquintinib group versus placebo. 2. The majority of adverse events were mild-to-moderate and were slightly more common among patients receiving fruquintinib. Evidence Rating Level: 1 (Excellent) Study Rundown: Colorectal cancer is the third-most prevalent cancer in the world and the second leading cause of death worldwide. Patients ....

Rating Level , Colonoscopy Screening , Colorectal Cancer , Between Aug , Colon Cancer , Metastatic Colorectal Cancer , Vegf Inhibitors , Chronic Disease ,

FDA Sets Priority Review for Fruquintinib as ASCO Data Confirm Safety Results

The therapy is designed to target multiple receptors and could address an unmet need in metastatic colorectal cancer. ....

United States , Jemala Colorecal , Awny Farajallah , Tus Fruquintinib , American Society Of Clinical Oncology Annual Meeting , Takeda Pharmaceuticals , Vanderbilt University Medical Center , Devices Agency , European Medicines Agency , Global Medical Affairs , Us Preventive Services Task , European Society Of Medical Oncology , Clinical Oncology Annual Meeting , Evidence Based Oncology , European Society , Medical Oncology , Medical Devices Agency , Prescription Drug User Fee , Services Task Force , New Drug Application , Published June , Vanderbilt University Medical , Colorectal Cancer ,

European Medicines Agency Validates MAA for Fruquintinib in Pretreated mCRC

The European Medicines Agency has validated and accepted a marketing authorization application for priority review for fruquintinib for the treatment of adult patients with pretreated metastatic colorectal cancer. ....

United States , Michael Shi , European Union , European Medicines Agency , Prescription Drug User Fee Act , Marketing Authorization Application , European Medicines , European Union Eu , Colorectal Cancer , European Medicines Agency ,